Share This Page
Drugs in ATC Class B05BC
✉ Email this page to a colleague
Drugs in ATC Class: B05BC - Solutions producing osmotic diuresis
| Tradename | Generic Name |
|---|---|
| MANNITOL 10% | mannitol |
| MANNITOL 10% IN PLASTIC CONTAINER | mannitol |
| MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER | mannitol |
| MANNITOL 15% | mannitol |
| MANNITOL 15% IN PLASTIC CONTAINER | mannitol |
| MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% | mannitol |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC B05BC solutions producing osmotic diuresis
ATC B05BC covers osmotic diuretic solutions used to promote diuresis. The core commercial exposure is driven by (1) injectable access in acute care, (2) hospital formulary contracting, and (3) patent-driven brand and manufacture exclusivity for specific salt forms, solution concentrations, packaging formats, and manufacturing methods. Patent fences typically cluster around pharmaceutical compositions (mannitol and related osmotic agents), infusion/solution presentation, and process claims for sterile manufacturing and stability. Competitive entry risk is mostly generic-to-sterile-solution, with limited patent freedom only when formulation and process claims are weak or have expired.
Scope note for precision: ATC B05BC is a drug class entry. Market and IP mapping depends on which specific osmotic diuretic solutions sit under the class in each territory (most materially mannitol IV and, in narrower markets, other osmotic diuretics). Patent estates also differ by strength, container, and manufacturing site. The patent landscape below is organized by the typical claim strata and by the points where generic and biosimilar-like dynamics do not apply (these are small-molecule injectables, so “biosimilar risk” is generally not the relevant comparator).
Which osmotic diuretic solutions sit in ATC B05BC and drive hospital demand?
Featured snippet answer: The market exposure in ATC B05BC is dominated by intravenous mannitol solutions used for osmotic diuresis in acute clinical settings, where demand tracks ICU volume, neurocritical care protocols, and intrahospital procurement cycles.
What are the main active ingredients and dosage forms?
In practice, ATC B05BC is treated commercially as an injectable osmotic diuretic solution category. The most common active is:
- Mannitol (IV infusion/bolus solution; strengths vary by product: commonly 5%, 10%, 20% in many jurisdictions)
- Other osmotic diuretics exist, but they usually have smaller footprint in the hospital infusion formulary than mannitol.
Where does volume come from?
Demand is typically concentrated in:
- ICU and neurocritical care (intracranial pressure management protocols)
- Emergency department and acute renal support pathways
- Perioperative and peri-nephric use protocols where osmotic diuresis is ordered
Commercial bottleneck: Many procurement decisions are made around availability, sterility assurance, shelf-life, and container format (glass vials vs plastic infusion bags), which interacts directly with formulation and manufacturing patents.
What patents protect mannitol and other osmotic diuretic solutions (B05BC)?
Featured snippet answer: The enforceable patent estate for osmotic diuretic IV solutions clusters around composition-and-stabilizer claims, sterile manufacturing/process claims, and packaging/container or fill-finish method claims tied to stability and shelf life.
Because the class is not a single drug, the patent landscape must be evaluated product-by-product. Still, most patent estates in osmotic diuresis solution markets have the same architectural pattern.
Composition patents: what do they usually claim?
Typical claim targets include:
- Specific mannitol concentration ranges and/or exact concentrations
- Specific solution characteristics (osmolarity targets, tonicity balance, pH windows)
- Inclusion or exclusion of excipients (buffers, stabilizers, antioxidants if used)
- Water-for-injection quality constraints and impurity profiles
Method-of-manufacture patents: where do strong claims appear?
Sterile solution estates often use process claims covering:
- Sterilization methods and cycle parameters (terminal sterilization vs aseptic processing)
- Filtration and hold-time controls
- Handling steps that reduce degradation and particulate formation
- Compatibility with specific packaging materials to reduce adsorption or leachables
Packaging and container patents: how do they affect entry?
Container and fill-finish can be claim-relevant through:
- Specific vial or bag materials that preserve solution stability
- Specific closure and sealing formats
- Methods to reduce particulate or maintain clarity
Practical enforcement pattern: Even when composition patents are weak, process or container patents can still restrict generic manufacturing until a workaround or licensing path is found.
How strong is the patent estate for osmotic diuretic IV solutions?
Featured snippet answer: Strength is usually highest for newer manufacturing and stability-driven patents (sterility assurance, particulate control, extended shelf-life) and lowest where claims rely only on broad concentration ranges that are easy to reproduce with conventional formulation know-how.
Typical “strong” indicators in this space
- Claims tied to specific concentration plus excipient system
- Process claims with measurable impurity/particulate thresholds
- Patents linked to data packages for stability that justify a new container format or manufacturing route
Typical “weak” indicators
- Broad Markush language that does not limit to a narrow stabilizer system
- Expired composition patents with only weak dependent claims remaining
- “Use” patents where the clinical ordering rationale is standard-of-care and easy to design around
When do osmotic diuretic solution patents lose exclusivity in the US and EU?
Featured snippet answer: Exclusivity timelines vary by branded product and by whether the estate is anchored in composition versus manufacturing. For many legacy mannitol injectables, regulatory exclusivity often lags behind patent expiry, so generic launch typically hinges on the last composition or method-of-manufacture claim rather than on regulatory data exclusivity.
What drives the clock?
In most jurisdictions, the path is:
- Primary drug substance or composition patent expiry
- Dependent claims expiry (formulation and concentration-specific)
- Manufacturing/process claim expiry
- Then generic substitution or competitive sales ramp
US-specific timing constructs
For small-molecule injectables:
- Orange Book listing determines which patents are asserted against generic applicants
- Paragraph IV challenges can occur only if listed patents still have unexpired terms
For a precise “loss of exclusivity” timetable by product, you need the exact NDC-Orange Book listing set. Without product-level inputs, a complete and accurate timeline cannot be stated.
What is the Orange Book status for B05BC osmotic diuretic products?
Featured snippet answer: Orange Book status depends on the specific marketed product (NDC) and the patent listing set. Without the product identifiers (NDC/active/holder), a complete Orange Book map for the entire ATC class cannot be produced.
What to check in Orange Book (what matters for market entry)
- Listed patents’ expiration dates
- Patent types (composition vs method vs formulation vs packaging)
- Whether the applicant is a label match or uses different strengths or container systems
How do Paragraph IV challenges typically work for injectable osmotic diuretics?
Featured snippet answer: In osmotic diuretic solutions, Paragraph IV dynamics usually center on sterile manufacturing method patents and composition/excipient claims that are listed for the relevant NDC/strength. When the generic can file a label or formulation carve-out, the litigation settlement often involves narrow product launch schedules.
Common litigation outcomes that shape the market
- Settlement agreements that allow earlier launch of one strength but delay another
- Cross-licenses for manufacturing improvements
- “Design-around” agreements where the generic changes excipients or sterilization conditions
Which companies are challenging patents for osmotic diuretic solutions?
Featured snippet answer: The challenger set in this class typically includes generic sterile-injectable specialists and large generics that have sterile filling capacity and packaging line flexibility. Brand holders often defend with combination estates that include both formulation and process patents.
A complete and accurate list of defendants, paragraph IV filers, and asserted patents cannot be provided without product-level Orange Book and litigation dockets.
What formulations are protected for mannitol solutions (strength, pH, excipients)?
Featured snippet answer: Formulation patents protect not just mannitol concentration, but also stability-critical attributes such as pH window, clarity/particulate performance, osmolarity targets, and the excipient system used to maintain solution integrity.
Strength-by-strength IP is common
Generics often attempt to launch at the same:
- Strength (for example 5%, 10%, 20% equivalents)
- Osmolarity or tonicity targets
- Container format (vial vs bag)
Excipient and impurity constraints
Sterile diuretic solutions are sensitive to:
- Breakdown products that increase with time and temperature
- Particulate formation or visible particulates that trigger compliance issues
Claims that anchor these attributes to defined manufacturing and formulation parameters can materially deter entry.
What patent barriers block generic entry for osmotic diuretic IV solutions?
Featured snippet answer: Patent barriers are strongest when the remaining claims cover sterility assurance, hold-time, filtration parameters, and container compatibility, not just the presence of mannitol.
Practical design-around zones
- Change sterilization method if it avoids process claim infringement
- Adjust excipient system (if permitted) to avoid composition claim scope
- Select a different container material only if stability data and regulatory comparability support it
- Modify particle-control steps
In many cases, even a successful design-around still faces manufacturing validation and cGMP process transfer risk, which affects speed to market.
How does the patent landscape differ across geographies (US vs EU vs UK)?
Featured snippet answer: US practice is driven by Orange Book-listed patents and Paragraph IV litigation posture. EU practice relies on national patent enforcement and regulatory pathways that do not map 1:1 to Orange Book mechanisms.
EU patent reality for injectables
- Composition and process patents are enforceable nationally
- SPCs (where available) can extend some exclusivity for specific products
- Generic entry is often constrained by the breadth of enforceable patents in the specific country where the generic supplies
UK and post-Brexit effect
- Patent enforcement remains national
- Litigation strategy and injunction risk can shape launch timing similarly to other European systems
A complete cross-geography mapping requires country-specific patent families for each marketed product.
What is the competitive landscape for osmotic diuretic solutions?
Featured snippet answer: Competition is mostly generic substitution for established mannitol IV solutions, with differentiation based on availability, container format, shelf-life, and the ability to clear IP barriers for each strength and NDC/packaging SKU.
Key commercial levers
- Hospital GPO contracting and tendering
- ICU stock continuity and supply reliability
- Pricing spread between brand and authorized generics
- Packaging line compatibility with infusion systems
IP’s role in price and access
Where patent fences remain, brand maintains pricing power via:
- Exclusivity-backed supply assurance
- Limited number of approved sources
- Tender preference for guaranteed delivery
When IP barriers fall, pricing compression typically accelerates with multi-source supply.
Key Takeaways
- ATC B05BC osmotic diuresis solutions are commercially anchored in injectable small molecules, with mannitol IV as the main market driver.
- Patent estates typically concentrate on composition (concentration/excipient/pH and stability-linked attributes) and sterile manufacturing/process and sometimes container compatibility.
- Generic entry risk is most often determined by the last remaining formulation or process claim that is listed for the relevant product strength and packaging.
- Market dynamics in acute care are shaped by availability and packaging, which can become de facto IP barriers even when composition claims weaken.
- A complete exclusivity timetable and Orange Book/litigation map requires product- and NDC-specific data; without it, only class-level dynamics and claim-type patterns can be stated.
FAQs
1) What patent claim types most often delay generic launch of IV mannitol?
Composition (exact concentration plus excipient/pH) and sterility/process claims tied to filtration, hold times, and particulate/impurity thresholds.
2) Can generics avoid infringement by switching vial vs bag for osmotic diuretic solutions?
Only if container-related claims are weak or design space is not claimed; otherwise container compatibility patents and stability-linked manufacturing claims can block entry.
3) What settlement patterns are common in injectable sterile product Paragraph IV cases?
Strength-by-strength launch timing, narrow design-around licensing, and phased supply commitments.
4) Are “biosimilar-style” risks relevant to osmotic diuretic solutions?
No. These are small-molecule solutions; the risk framework is generic-to-innovator based on composition/process patent scope.
5) What hospital buying factors interact with IP barriers for IV osmotic diuretics?
Container format, shelf-life, supply continuity, and line compatibility with hospital infusion protocols.
References
No sources were cited because no product-specific regulatory, Orange Book, patent, or litigation identifiers were provided.
More… ↓
